Physician profile
Rodney E Powell
NPI 1821063959
$1,754.39
in general payments reported to CMS, 2019-2025
14 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.24 · 2020: $146 · 2021: $88.53 · 2022: $190 · 2023: $489 · 2024: $313 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,271.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $342.39 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $335.19 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $214.57 | 2020-2025 | |
| Cvrx, INC. | $154.39 | 2025 | Barostim Neo System |
| Amgen INC. | $131.86 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $130.98 | 2019-2023 | Xarelto |
| Dexcom, INC. | $97.68 | 2023 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $81.10 | 2022-2025 | Watchman, Watchman Flx |
| Impulse Dynamics (USA) INC. | $75.65 | 2022-2023 | Optimizer |
| Bayer Healthcare Pharmaceuticals INC. | $74.78 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $43.56 | 2022-2023 | Farxiga |
| Scpharmaceuticals INC. | $26.92 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $23.22 | 2024 | Arcalyst |
| Abbott Laboratories | $22.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodney Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.